Literature DB >> 7873122

Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies.

K Ishiwata1, K Inami, T Sasaki, T Nozaki, M Senda.   

Abstract

We characterized [3H]nemonapride ([3H]NEM, [3H]YM-09151-2) binding to dopamine D2 receptors. In mice given [3H]NEM with and without sulpiride, the in vivo specific binding of the [3H]NEM to the D2 receptors in the striatum was assessed: SBin vivo-1, striatal uptake minus cerebellar uptake; and SBin vivo-2, uptake in the control mice minus uptake in the sulpiride-treated mice. Tissue homogenates were divided into cytosol and the membrane binding fraction (MB). When the MB was incubated in vitro with sulpiride, the dissociated and nondissociated fractions were defined as the ex vivospecific binding (SBex vivo) and the ex vivo nonspecific binding (NBex vivo), respectively. HPLC revealed that most of the radioactivity in the MB was [3H]NEM, whereas metabolites were found in the cytosol. In the striatum, the SBex vivo increased with time (50% of the total tissue uptake at 60 min), and was equivalent to the SBin vivo-2. The SBin vivo-1 was comparable to the MB. In the cerebral cortex and cerebellum, the SBex vivo decreased with time and the SBex vivo/free [3H]NEM ratios were smaller than those in the striatum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873122     DOI: 10.1007/bf01277948

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  22 in total

1.  Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements.

Authors:  G Blomqvist; S Pauli; L Farde; L Eriksson; A Persson; C Halldin
Journal:  Eur J Nucl Med       Date:  1990

2.  Positron emission tomography studies of neurotransmitter systems.

Authors:  G V Sawle; D J Brooks
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

3.  Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.

Authors:  J K Chivers; W Gommeren; J E Leysen; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1988-06       Impact factor: 3.765

4.  Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.

Authors:  M Terai; S Usuda; I Kuroiwa; O Noshiro; H Maeno
Journal:  Jpn J Pharmacol       Date:  1983-08

Review 5.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

6.  In vivo dopamine receptor assessment for clinical studies using positron emission tomography.

Authors:  J A Swart; J Korf
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

7.  Autoradiography of dopamine D2 receptors using [3H]YM-09151-2.

Authors:  R F Cox; B L Waszczak
Journal:  Eur J Pharmacol       Date:  1991-06-18       Impact factor: 4.432

8.  [18F]-N-Methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain.

Authors:  C D Arnett; J S Fowler; A P Wolf; C Y Shiue; D W McPherson
Journal:  Life Sci       Date:  1985-04-08       Impact factor: 5.037

9.  In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.

Authors:  C Köhler; G Karlsson-Boethius
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo.

Authors:  S B Ross; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

View more
  1 in total

1.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.